Premium
Plasma growth hormone (GH)‐releasing hormone levels in patients with lung carcinoma
Author(s) -
Schopohl Jochen,
Lose Marco,
Frey Chris,
Wolfram Gernot,
Huber Rudolf,
Permanetter Willibald,
Pawel Joachim,
Müller O. Albrecht,
Werder Klaus
Publication year - 1991
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1991.tb00326.x
Subject(s) - medicine , hormone , small cell carcinoma , carcinoma , lung , endocrinology , radioimmunoassay , small cell lung carcinoma
SUMMARY objective The aim was to investigate the serum levels of growth hormone releasing hormone and GH in patients with lung carcinoma design After an overnight fast a plasma sample was collected for determination of growth hormone releasing hormone and GH patients The investigation was performed in 28 patients with non small cell lung carcinoma, in 44 patients with small cell lung carcinoma, and 10 patients with non malignant lung disease. A group of 37 normal subjects served as control measurements Growth hormone releasing hormone and GH were determined by radloimmunoassayresults Patients with small cell lung carcinoma showed higher plasma growth hormone releasing hormone levels (49·9±4 ng/l) than control subjects (16·3±2·1 ng/l; p>0·05), patients with non small cell lung carcinoma (23·9± 8·8 ng/l; p>0·05), and patients with non malignant lung disease (12·7±5·5; P > 0·05). Basal GH level was lower than 5 μ g/l In all patients except five patients with small cell lung carcinoma and one patient with non small cell lung carcinoma . conclusions The higher plasma growth hormone releasing hormone levels in patients with small cell lung carcinoma compared to normal controls and patients with non small cell lung carcinoma and patients with non malignant lung disease, confirm the frequent neuroendocrine activity of this particular tumour